Howard H. Chertkow
Experienced in Progressive Supranuclear Palsy

Howard H. Chertkow

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Progressive Supranuclear Palsy
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Howard Chertkow practices in Toronto, Canada. Mr. Chertkow is rated as an Experienced expert by MediFind in the treatment of Progressive Supranuclear Palsy. His top areas of expertise are Dementia, Alzheimer's Disease, Developmental Dysphasia Familial, and Primary Progressive Aphasia.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Progressive Supranuclear Palsy.

Gender
Male

Locations

Toronto, ON, Canada
Other Locations
Montreal, QC, Canada
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Enrollment Status: Recruiting
Publish Date: November 21, 2024
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
Enrollment Status: Terminated
Publish Date: May 06, 2025
Intervention Type: Drug
Study Drugs: Perindopril, Telmisartan
Study Phase: Phase 2
Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease
Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease
Enrollment Status: Suspended
Publish Date: January 25, 2023
Intervention Type: Device
Study Phase: Not Applicable
View 3 Less Clinical Trials

93 Total Publications

Five-Year Trajectory of Mild Cognitive Impairment: Insights from a Primary Care Memory Clinic.
Five-Year Trajectory of Mild Cognitive Impairment: Insights from a Primary Care Memory Clinic.
Journal: Canadian journal on aging = La revue canadienne du vieillissement
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chertkow's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile